Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
11/2003
11/26/2003CN1457766A Mucilage antiseptic medicine composition capable of being locally administratied and sustainably released and its preparing method
11/26/2003CN1128800C Pyrolo [2,3-d] pyrimidine compounds and its composition and use
11/26/2003CN1128798C Pharmaceutically active tricyclic amines
11/26/2003CN1128789C Benzocycloheptathiophene compounds
11/26/2003CN1128625C Dengtai tree extract and its preparing method and use
11/26/2003CN1128624C Process for preparing powdered medicine to treat rhinitis and nasosinusitis
11/25/2003US6653508 Use treating various medical conditions, including pain
11/25/2003US6653493 Lipoxin compounds and their use in treating cell proliferative disorders
11/25/2003US6653347 For therapy
11/25/2003US6653313 1,4-dihydropyridine compounds as bradykinin antagonists
11/25/2003US6653312 Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same
11/25/2003US6653310 For therapy of disease states mediated by the chemokine, Interleukin-8 (IL-8)
11/25/2003US6653304 Antiarthritic agents; skin disorders; anticarcinogenic agents
11/25/2003US6653301 For therapy of cancer, diabetes and Alzheimer's disease
11/25/2003US6653300 Pyrazole compounds useful as protein kinase inhibitors
11/25/2003US6653292 Stimulating Th1 pattern of immune activation, cytokine production, NK lytic activity and B cell proliferation; modulating with nucleic acid sequences containing unmethylated CpG dinucleotides
11/25/2003US6653134 Obtaining a bone marrow sample from a human, isolating stromal cells, and administering to the central nervous system of the patient; treating a genetic disease, a tumor, trauma and stroke
11/25/2003US6652856 Method for the treatment of fibrosis
11/25/2003US6652855 Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
11/20/2003WO2003095678A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
11/20/2003WO2003095667A2 Autoimmune conditions and nadph oxidase defects
11/20/2003WO2003095644A1 Novel proteins and dnas thereof
11/20/2003WO2003095637A1 Combination of a growth factor and a protease enzyme
11/20/2003WO2003095613A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
11/20/2003WO2003095498A1 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
11/20/2003WO2003095454A1 1ß-METHYLCARBAPENEM DERIVATIVE FOR ORAL ADMINISTRATION
11/20/2003WO2003095452A1 Substituted pyrroline kinase inhibitors
11/20/2003WO2003095424A1 Process for producing shogaol and intermediates for the synthesis thereof
11/20/2003WO2003095420A1 Hydroxy tetrahydro-naphthalenylurea derivatives
11/20/2003WO2003094968A2 Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
11/20/2003WO2003094967A2 New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
11/20/2003WO2003094960A2 Mucosal combination vaccines for bacterial meningitis
11/20/2003WO2003094957A2 Methods of therapy for inducing tolerance
11/20/2003WO2003094932A1 Carbon monoxide as a biomarker and therapeutic agent
11/20/2003WO2003094911A1 Hepatoprotective activity of 10-o-p-hydroxybenzoyiaucubin
11/20/2003WO2003094906A1 Anti-rhinovirus active agents
11/20/2003WO2003094901A1 Medicament for treating and preventing pneumoconiosis
11/20/2003WO2003094892A1 Conversion of amorphous material to a corresponding crystalline material by spray drying and utilization of the crystalline spray dried material in drug formulations
11/20/2003WO2003094890A1 Capsules for dry powder inhalers and methods of making and using same
11/20/2003WO2003094861A2 Bis-benzimidazoles and related compounds as potassium channel modulators
11/20/2003WO2003094859A2 Epha2 monoclonal antibodies and methods of use thereof
11/20/2003WO2003094840A2 Induction of antigen specific immunologic tolerance
11/20/2003WO2003094836A2 Methods and products for enhancing immune responses using imidazoquinoline compounds
11/20/2003WO2003094831A2 Novel diazabicyclic biaryl derivatives
11/20/2003WO2003094830A2 Novel azacyclic ethynyl derivatives
11/20/2003WO2003087062A3 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
11/20/2003WO2003070192A9 Compositions and methods for surrogate antibody modulation of an immune response and transport
11/20/2003WO2003054012A3 Leptin proteins
11/20/2003WO2003049752A3 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
11/20/2003WO2003042357A3 Enzymes
11/20/2003WO2003038110A3 7118, a human arginine n-methyltransferase family member and uses therefor
11/20/2003WO2003027076A3 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
11/20/2003WO2003017946A3 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
11/20/2003WO2003016468A3 Antagonistic anti-htnfsf13b human antibodies
11/20/2003WO2003009873A3 Use of pulmonary surfactant as humectant
11/20/2003WO2003000864A3 Nucleic acid-associated proteins
11/20/2003WO2003000699A8 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain
11/20/2003WO2002102315A3 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7
11/20/2003WO2002095011A3 Inactivation of genes of the mep pathway
11/20/2003WO2002090530A3 Kinases and phosphatases
11/20/2003WO2002083736A3 G-protein coupled receptor molecules and uses thereof
11/20/2003WO2002079249A3 New polynucleotides and polypeptides of the ifn$g(a)-21 gene
11/20/2003WO2002061110A8 Nucleic acid derivatives
11/20/2003WO2002060935A3 A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences
11/20/2003US20030216586 Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them
11/20/2003US20030216549 Comprises modified chemokine for use as antiinflammatory, viricidal or antiallergenic agent
11/20/2003US20030216481 Cyclooxygenase inhibitors; osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse
11/20/2003US20030216447 Compositions and method for treating infection in cattle and swine
11/20/2003US20030216446 Aryl ureas as kinase inhibitors
11/20/2003US20030216427 Amine derivatives for the treatment of apoptosis
11/20/2003US20030216419 Isomeric fused pyrrolocarbazoles and isoindolones
11/20/2003US20030216417 Substituted anilino-quinoline compounds and use thereof
11/20/2003US20030216413 Catecholamine pharmaceutical compositions and methods
11/20/2003US20030216404 Hydroxamic acid derivatives
11/20/2003US20030216401 Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles
11/20/2003US20030216392 Aryl or heteroaryl substituted ethylcarbonylsulfonamide derivatives used as inhibitors of neutrophils chemotaxis and degranulation induced by interleukin 8
11/20/2003US20030216389 Therapeutic morpholino-substituted compounds
11/20/2003US20030216383 Compounds useful as reversible inhibitors of cysteine proteases
11/20/2003US20030216381 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer
11/20/2003US20030216375 Sulfonamide substituted diphenyl thiourea compounds; use thereof in treating IL-8, GRO alpha, GRO beta, GRO gamma, NAP-2, and ENA-78 mediated diseases
11/20/2003US20030216367 In perimenopausal, menopausal, and postmenopausal women through the sequential administration of combinations of conjugated estrogens and trimegestone
11/20/2003US20030216324 Five-member heterocyclic compounds substituted with an alpha-amino carbonyl group; antiasthma agents
11/20/2003US20030215879 Comprise enzymatic polypeptide for use in the treatment of inflammation; aniinflammatory agents
11/20/2003US20030215829 Nuclear hormone receptors
11/20/2003US20030215512 Stable glassy state powder formulations
11/20/2003US20030215508 Sustained release portion of unit dose containing guaifenesin, dextromethorphan and a release-delaying matrix contains a hydrophilic polymer and a water insoluble polymer, immediate release portion containing guaifenesin
11/20/2003US20030215457 Comprising a nucleic acid, a polypeptide encoded by the nucleic acid, and a compound, preferably an antibody or fragment thereof, that binds to the polypeptide, preferably binding to the extracellular domain of LIV-1 polypeptide
11/20/2003US20030215443 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
11/20/2003US20030214409 System and method for transparent early detection, warning, and intervention during a medical procedure
11/20/2003US20030213920 Methods for sterilizing preparations containing albumin
11/20/2003CA2492394A1 Induction of antigen specific immunologic tolerance
11/20/2003CA2492044A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
11/20/2003CA2485999A1 Mucosal combination vaccines for bacterial meningitis
11/20/2003CA2485527A1 Substituted pyrroline kinase inhibitors
11/20/2003CA2485373A1 Epha2 monoclonal antibodies and methods of use thereof
11/20/2003CA2484835A1 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
11/20/2003CA2484827A1 Anti-rhinovirus active agents
11/20/2003CA2484770A1 Carbon monoxide as a biomarker and therapeutic agent
11/20/2003CA2484276A1 Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
11/20/2003CA2484272A1 New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
1 ... 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 ... 878